The annual treatment cost is less than 20,000 yuan. The fifth domestic PD-1 pricing flows out

A few days ago, the fifth domestically produced PD-1-Kangfang Biologics and CP Tianqing's Paimrizumab injection (Annico) is priced out: the retail price is 4875 yuan/100mg, combined with the supporting drug policy.

Spend less than 20,000 a year

On August 5 this year, Annikol was approved to be marketed for the treatment of patients with relapsed or refractory classic Hodgkin’s lymphoma (r/r cHL) after at least second-line chemotherapy

Anniker is a recombinant humanized anti-PD-1 monoclonal antibody independently developed by Kangfang Biology.

According to the pricing plan and patient assistance plan that have flowed out recently:

The price per bottle of Anike is 4875 yuan/100mg (200mg each time, once every 2 weeks);

According to the Beijing Kangmeng Charity Foundation, Anike’s patient assistance program is specifically: the first round of assistance program adopts the 2+1 model, that is, after the patient purchases and uses 2 cycles (4), 1 cycle (2) is given away.

In terms of pricing, Anicol has the highest unit specifications compared to the 4 domestically-made PD-1s that have been on the market.

Low price entry under fierce competition

It is reported that Chia Tai Tianqing, China Biopharmaceuticals, and Kangfang Biotechnology have jointly stated that Anike’s pricing and rescue plan is based on its more competitive and differentiated considerations in terms of efficacy and safety compared to the same period last year, taking into account the current PD- 1 The competition pattern of the monoclonal antibody market is also preparing for the entry of other major indications into medical insurance in 2022

The current domestic PD-1 volume is serious.

In addition, in terms of the indications approved by Annik, Hodgkin’s lymphoma is not a major disease, and BeiGene, Hengrui, and Xinda’s PD-1 have all been approved for this indication.

Therefore, Annik's low price entry at this time is a strategy

According to a report from the Health and Awareness Bureau, some people in the industry said that the average market price of PD-1 is about 50,000 yuan, which does not seem to be high, but public hospitals will consider the issue of medical insurance coverage

In addition, with CP Tianqing’s advantages in channels, Annik’s future sales may not be bad

summary

The treatment cost of 39,000 yuan / 2 years has indeed refreshed people's impression of the price of PD-1

To what extent can the annual cost of PD-1 be reduced? This year's medical insurance negotiations may reveal the answer

Note: The original text has been deleted